Halogen-Substituted Isoindoline Compounds for Oral GSPT1 Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein regulatory drugs, particularly those targeting GSPT1, lack effective oral administration options and have variable efficacy and safety due to minor molecular changes, and halogen-substituted isoindoline compounds have not been utilized for protein regulation.
Innovation Solution
Development of halogen-substituted isoindoline compounds with specific structural variations to enhance regulatory effects on proteins like GSPT1, offering improved anti-tumor activity and safety through oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous administration is used for protein regulatory drugs, then therapeutic efficacy is achieved, but convenience and cost-efficiency deteriorate
Solution Approach 1:
The patent modifies the molecular structure parameters of the drug compound by introducing halogen substituents (fluorine, chlorine, bromine, or iodine) at specific positions on the isoindoline ring system. This structural parameter change enables the drug to achieve oral bioavailability while maintaining therapeutic efficacy against GSPT1, thereby resolving the contradiction between intravenous administration requirements and oral convenience.
2Adaptability or versatility
If minor molecular changes are made to protein regulators, then development flexibility is improved, but metabolic stability and biological activity deteriorate
Solution Approach 1:
The patent applies local quality modification by introducing halogen substituents at specific local positions (R4 and R5) on the isoindoline molecular structure. This localized modification at key positions enables optimization of metabolic stability and biological activity while maintaining overall molecular framework, resolving the contradiction between structural flexibility and functional reliability.
3Reliability
If halogen-substituted isoindoline compounds are developed, then anti-tumor activity is improved, but hERG channel inhibition increases
Solution Approach 1:
The patent employs local quality modification by selectively positioning halogen substituents at specific locations (R4 and R5) on the isoindoline structure. This localized approach allows optimization of anti-tumor activity through enhanced GSPT1 degradation while controlling hERG channel interaction, thereby resolving the contradiction between therapeutic efficacy and cardiac safety.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying halogen substitution patterns (different halogen types at R4 and R5 positions) to fine-tune the balance between anti-tumor activity and hERG channel inhibition. This parameter optimization enables achievement of therapeutic efficacy with reduced cardiac toxicity.
Data Source
AI summary
A halogen-substituted isoindoline compound represented by formula I below and use thereof are provided. The compound has significantly better anti-tumor activity, and can be prepared into an oral dosage form.